raxibacumab
Sign in to saveAlso known as Abthrax
Raxibacumab is a human monoclonal antibody intended for the prophylaxis and treatment of inhaled anthrax. Its efficacy has been proven in rabbits and monkeys. In December 2012 raxibacumab was approved in the United States for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 4 more facts
- World Health Organisation international non-proprietary name
- raxibacumab
- has characteristic
- biopharmaceutical
- subject has role
- monoclonal antibody
- legal status (medicine)
- boxed warning
Sources (2)
via Wikidata · CC0
~2 min read
Encyclopedic overview
4 sectionsContents
- Side effects
- Pharmacology
- Development history
- References
Raxibacumab is a human monoclonal antibody intended for the prophylaxis and treatment of inhaled anthrax. Its efficacy has been proven in rabbits and monkeys. In December 2012 raxibacumab was approved in the United States for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
The antibody was discovered in a joint venture between Cambridge Antibody Technology and Human Genome Sciences. Cambridge Antibody Technology discovered the antibody to Human Genome Sciences's target and, in 2012, HGS was purchased by GlaxoSmithKline (GSK). In 2017, CAT was acquired by Emergent BioSolutions
Excerpted from Wikipedia’s “raxibacumab” article, available under the CC BY-SA 4.0 licence.
Available in 11 languages
via Wikidata sitelinks · CC0